Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDP5290
- Development stage
- Preclinical
- Lead developer
- Beatson Institute
- Modality
- Small Molecules
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Sublingual, Buccal, Transdermal, Intradermal, Intrathecal, Intraarticular, Intralesional, Intraperitoneal, Intra-arterial, Parenteral
01
Overview
BDP5290 (also known as BDP00005290) is a potent, selective small-molecule inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinases (MRCK), specifically targeting MRCKα (CDC42BPA) and MRCKβ (CDC42BPB). Developed by the Cancer Research UK Beatson Institute, BDP5290 acts by binding to the nucleotide-binding pocket of the MRCK kinase domain, thereby blocking the phosphorylation of myosin light chain (MLC). This inhibition disrupts actin-myosin contractility, leading to the reduction of cancer cell motility, migration, and invasion. BDP5290 has been investigated in preclinical research for its potential to overcome immunotherapy resistance and suppress metastasis in various cancers, including breast cancer, colorectal cancer, and squamous cell carcinoma.
- Other names
- 4-chloro-1-(4-piperidyl)-N-[5-(2-pyridyl)-1H-pyrazol-4-yl]pyrazole-3-carboxamide
02
Targets
CDC42BPA (CDC42 binding protein kinase alpha)CDC42BPB (MRCKβ)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on BDP5290.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDP5290.